ORLANDO -- In this video, Ann S. LaCasce, MD, MMSc, discusses highlights in mantle cell lymphoma presented at ASH Annual Meeting and Exposition.
Highlights included data on triplet therapies, which included Bruton tyrosine kinase inhibitors, BCL2 inhibitors and CD20 antibodies.
"All of these looked really good," LaCasce, associate professor of medicine at Harvard Medical School and director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology, said. "I do think we're going to need longer-term follow-up and randomized trials to really assess the long-term benefit."